The short answer: No FDA label for a common mood stabilizer says drinking is safe. The Depakote (valproate) and Seroquel (quetiapine) Medication Guides both tell patients not to drink at all, and the Tegretol (carbamazepine) label warns of a possible additive sedative effect. The lithium and lamotrigine labels carry no alcohol interaction statement, but that silence is not approval. Alcohol still fragments the second half of the night, and sleep loss is a documented trigger for mania.

What do the FDA labels say about alcohol?

The labels are not consistent, so read them one at a time.

  • Valproate (Depakote, Depakene). The Depakote label Medication Guide states: "Do not drink alcohol while taking Depakote. Depakote and alcohol can affect each other causing side effects such as sleepiness and dizziness." The patient counseling section adds that valproate products "may produce CNS depression, especially when combined with another CNS depressant (e.g., alcohol)."
  • Carbamazepine (Tegretol). The Tegretol label says: "Caution should be exercised if alcohol is taken in combination with Tegretol therapy, due to a possible additive sedative effect." Its Medication Guide is blunter: "Do not drink alcohol or take other drugs that make you sleepy or dizzy while taking TEGRETOL until you talk to your healthcare provider."
  • Quetiapine (Seroquel). The Seroquel label reports that the drug "potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine."
  • Lamotrigine (Lamictal). The Lamictal label has no alcohol interaction statement anywhere. The word alcohol appears once, as a rare adverse reaction called alcohol intolerance. Its Medication Guide section on what to avoid mentions only driving and hazardous machinery.
  • Lithium. The lithium carbonate label also lists no alcohol interaction. The oral solution form actually contains alcohol 0.3% v/v as an inactive ingredient.

Silence in a label is not a green light. The National Institute on Alcohol Abuse and Alcoholism lists mood stabilizers among medicines that interact with alcohol. It names both valproic acid and lithium, with effects that include drowsiness, dizziness, tremors, impaired motor control, and liver damage from valproic acid.

Does the interaction work the same way for every drug?

No. Three separate mechanisms operate, and each points to a different risk.

Added CNS depression. Alcohol slows the central nervous system. So do valproate, carbamazepine, and quetiapine. The Tegretol label notes that dizziness, drowsiness, unsteadiness, and nausea are its most frequent adverse reactions, especially early in treatment. Alcohol on top of that impairs more than either alone. All three labels warn about driving and machinery.

Liver load. Carbamazepine "is metabolized in the liver," with CYP3A4 identified as the major enzyme. Valproate carries a boxed warning stating that "hepatic failure resulting in fatalities has occurred in patients receiving valproate." The Depakote Medication Guide asks patients to tell the prescriber before starting if they drink alcohol. Heavy drinking is itself a liver stressor, so the two overlap.

Fluid, sodium, and kidney handling. Lithium is the odd one out. Its boxed warning says toxicity "is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations." The label lists "volume depletion or dehydration" and changes in sodium and potassium among the factors that raise that risk. It also tells patients to keep a normal diet including salt, plus 2,500 to 3,000 mL of fluid during initial stabilization. A heavy drinking episode with vomiting, skipped meals, or extra urine output shifts exactly those variables. Our guide to mood stabilizers explains how these drug classes differ in other ways.

How does alcohol affect sleep, and why does that matter?

Alcohol is a poor sleep aid. A 2020 review in Neuropsychopharmacology by NIAAA researchers summarized the sleep laboratory evidence. Intoxicating doses shorten the time to fall asleep by only about 5 minutes at doses of 0.9 g/kg or more. They then "lead to increases in SWS early in the night but a deterioration of sleep quality (i.e., an increase in N1 and decrease in SWS later in the night)". Time spent awake falls early in the night and rises later. Drinking across multiple days does not produce habituation.

That second-half fragmentation is what matters in bipolar disorder. In a study of 3,140 people with bipolar disorder in the British Journal of Psychiatry, sleep loss triggering episodes of high mood was associated with bipolar I subtype (odds ratio 2.81, 95% CI 2.26 to 3.50) and female gender (odds ratio 1.43, 95% CI 1.17 to 1.75). If disrupted sleep is one of your episode triggers, a drink that wrecks your 3 a.m. works against the medication. More on sleep and alcohol sits at insomnia.md.

How often do bipolar disorder and alcohol use disorder occur together?

Often enough that clinicians treat it as expected. A systematic review and meta-analysis in the Journal of Affective Disorders pooled 22 large multi-site studies and 56 individual studies of treatment-seeking patients. Alcohol use disorder was the most common comorbidity at 42%, ahead of cannabis use at 20% and other illicit drug use at 17%. Rates were similar in bipolar I and bipolar II. A 2021 review in Frontiers in Psychiatry puts lifetime co-occurrence at 40% to 70% across both subtypes. For scale, the National Epidemiologic Survey on Alcohol and Related Conditions (N = 43,093) estimated lifetime bipolar I prevalence at 3.3% in US adults.

What does heavy drinking do to the course of the illness?

The same review describes the pattern in people with both conditions: earlier onset, delayed recovery from episodes, more frequent mood switches, rapid cycling, mixed states, more severe depression, and more suicidal ideation. It cites a Brazilian study in which 68% of patients with both conditions had attempted suicide, compared with 35% of those without alcohol use disorder. The authors call the relationship bidirectional.

Treatment results are mixed. In trials it summarizes, quetiapine reduced depressive symptoms faster than placebo but had no effect on any alcohol outcome. Valproate reduced heavy drinking days in a controlled trial of 59 patients without improving mood scores. Concurrent substance use also predicts poorer lithium response. None of that argues for stopping medication, and quitting abruptly is its own hazard: see what happens if you stop taking lithium.

How do clinicians screen for and treat both conditions?

Screening is routine primary care. In 2018 the US Preventive Services Task Force issued a grade B recommendation to screen all adults 18 and older for unhealthy alcohol use and offer brief behavioral counseling. It names two short tools: the three-question AUDIT-C and the NIAAA Single Alcohol Screening Question.

The thresholds come from NIAAA. A standard US drink is 0.6 fluid ounces or 14 grams of pure alcohol. Binge drinking means reaching a blood alcohol concentration of 0.08%, roughly five drinks for men or four for women in about two hours. Heavy drinking means five or more drinks in a day or 15 per week for men, and four or more in a day or eight per week for women. NIAAA also states that some people should avoid alcohol completely, including anyone taking prescription medications that interact with it.

NIAAA notes that three medications are currently approved in the United States to help people stop or reduce drinking: naltrexone, acamprosate, and disulfiram. The naltrexone label is indicated for alcohol dependence and reports a trial of 104 patients in which abstention rates were 51% versus 23% on placebo, with relapse at 31% versus 60%. The Frontiers in Psychiatry authors argue that both disorders "should be treated in one setting and by the same therapeutic team," with cognitive behavioral therapy and integrated group therapy carrying the strongest psychosocial evidence.

The bottom line

The labeled answer varies by drug, and no mood stabilizer label endorses drinking. Valproate, carbamazepine, and quetiapine add sedation, and two of them add liver concerns. Lithium reacts to fluid and sodium shifts rather than to alcohol itself. Lamotrigine has no labeled interaction, which is the weakest case against a drink and still not a case for one. Alcohol also breaks the back half of the night, the mechanism most likely to cost you a stable month. Bring your prescriber real numbers about how much you drink.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Do not change how you take a mood stabilizer, and do not stop heavy drinking abruptly, without talking to a clinician first.